TABLE 5.

Analysis of the V1 hypervariable region of the SIV-specific sequences amplified from the PBMC of macaques challenged with uncloned SIVmne

Animal	Challenge outcome	% of sequence of typea:		SD	ne
		E11S	Variant
Control
Expt 1
91319	Infected	13.34	86.66	±2.35	3
91320	Infected	99.95	0.05	±0.05	2
91323	Infected	20.00	80.00	±5.00	2
91324	Infected	27.50	72.50	±2.50	2
Expt 2
92170	Infected	0.95	99.05	±0.96	4
92179	Infected	3.67	96.33	±4.49	3
93032	Infected	95.75	4.25	±4.25	2
Expt 3
91064b	Infected	99.95	0.05	±0.05	2
91070	Infected	96.00	4.00	±2.00	2
92168	Infected	5.87	94.13	±2.28	3
Immunized
Expt 1
87201	Infected	0.00	100.0	±0.00	2
87221	Infected	0.70	99.30	±0.70	2
87210c	Transient	90.00	10.00		1
87217	Protected
Expt 2
90073	Protected
90078	Transient	95.00	5.00	±6.40	3
90094	Infected	0.07	99.93	±0.09	3
Expt 3
J90304	Infected	98.66	1.34	±1.54	3
91250d	Transient	25.00	75.00		1
92163	Protected

^aThe proportion of E11S-type or variant-type sequences was determined by nucleotide sequence analysis of PCR amplified fragments cloned in M13 vectors, by PCR amplification with radiolabeled primers for quantification, or both. For every PCR analysis, DNA from cells infected with E11S or uncloned SIVmne was run as a control. Unless otherwise noted, all the samples were prepared from PBMC collected 2 weeks after challenge. 

^bPBMC sample was collected 4 weeks after infection. The proportion of E11S-type and variant-type sequences was constant from weeks 4 through 8 in this animal. 

^cPBMC sample was collected 4 weeks after infection, the only time when the proviral DNA was detected in this animal by nested PCR. 

^dData represent sequences amplified from lymph node samples collected 6 weeks after challenge, which was the only time we were able to amplify proviral DNA for this analysis. We were not able to amplify sufficient quantities of proviral DNA from the PBMC of this animal at any time for this analysis. 

^en, number of determinations made for each sample.